Compare Stocks: RDHL, INTS, PSTV, and CALC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CALC CalciMedica	$1.66 -1.2%	$2.80	$1.62 ▼ $36.00	$11.34M	0.83	191,234 shs	7,772 shs
INTS Intensity Therapeutics	$3.54 -3.2%	$4.19	$3.50 ▼ $43.50	$11.44M	2.76	40,400 shs	12,136 shs
PSTV Plus Therapeutics	$2.02 +1.5%	$3.07	$2.90 ▼ $23.42	$13.91M	1.4	116,506 shs	99,108 shs
RDHL Redhill Biopharma	$0.49 -3.9%	$0.63	$0.48 ▼ $2.61	$3.01M	4.96	843,499 shs	72,750 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CALC CalciMedica	-2.29%	-8.06%	-26.36%	-66.80%	-88.90%
INTS Intensity Therapeutics	-3.95%	-9.20%	-14.12%	-11.19%	-39.42%
PSTV Plus Therapeutics	0.00%	-1.97%	-34.75%	-54.46%	-87.10%
RDHL Redhill Biopharma	+1.10%	-8.07%	-23.52%	-40.18%	-72.53%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CALC CalciMedica	$1.66 -1.2%	$2.80	$1.62 ▼ $36.00	$11.34M	0.83	191,234 shs	7,772 shs
INTS Intensity Therapeutics	$3.54 -3.2%	$4.19	$3.50 ▼ $43.50	$11.44M	2.76	40,400 shs	12,136 shs
PSTV Plus Therapeutics	$2.02 +1.5%	$3.07	$2.90 ▼ $23.42	$13.91M	1.4	116,506 shs	99,108 shs
RDHL Redhill Biopharma	$0.49 -3.9%	$0.63	$0.48 ▼ $2.61	$3.01M	4.96	843,499 shs	72,750 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CALC CalciMedica	-2.29%	-8.06%	-26.36%	-66.80%	-88.90%
INTS Intensity Therapeutics	-3.95%	-9.20%	-14.12%	-11.19%	-39.42%
PSTV Plus Therapeutics	0.00%	-1.97%	-34.75%	-54.46%	-87.10%
RDHL Redhill Biopharma	+1.10%	-8.07%	-23.52%	-40.18%	-72.53%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CALC CalciMedica	2.20	Hold	$50.00	2,912.05% Upside
INTS Intensity Therapeutics	2.80	Moderate Buy	$7.00	98.02% Upside
PSTV Plus Therapeutics	2.33	Hold	$51.75	2,461.88% Upside
RDHL Redhill Biopharma	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest RDHL, INTS, PSTV, and CALC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2026	CALC CalciMedica	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/20/2026	CALC CalciMedica	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy
8/18/2026	INTS Intensity Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$5.00 ➝ $7.00
8/13/2026	CALC CalciMedica	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/13/2026	CALC CalciMedica	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
8/11/2026	INTS Intensity Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/3/2026	RDHL Redhill Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/29/2026	CALC CalciMedica	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/29/2026	CALC CalciMedica	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
7/21/2026	INTS Intensity Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	PSTV Plus Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)

(Data available from 9/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CALC CalciMedica	N/A	N/A	N/A	N/A	($2.30) per share	N/A
INTS Intensity Therapeutics	N/A	N/A	N/A	N/A	$4.94 per share	N/A
PSTV Plus Therapeutics	N/A	N/A	N/A	N/A	$0.72 per share	N/A
RDHL Redhill Biopharma	$290K	10.19	N/A	N/A	$0.83 per share	0.59

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CALC CalciMedica	-$29.56M	-$6.80	N/A	N/A	N/A	N/A	-863.40%	-155.24%	11/11/2026 (Estimated)
INTS Intensity Therapeutics	-$11.61M	-$3.57	N/A	N/A	N/A	N/A	-116.61%	-94.01%	11/5/2026 (Estimated)
PSTV Plus Therapeutics	-$22.39M	-$2.30	N/A	N/A	N/A	-230.24%	-198.48%	-73.13%	N/A
RDHL Redhill Biopharma	-$430K	$900.00	0.00	N/A	N/A	N/A	N/A	N/A	N/A

Latest RDHL, INTS, PSTV, and CALC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	PSTV Plus Therapeutics	-$0.88	-$1.31	-$0.43	-$1.31	$1.11 million	$0.41 million
8/11/2026	Q2 2026	CALC CalciMedica	-$1.4250	-$0.45	+$0.9750	-$2.25	N/A	N/A
8/11/2026	Q2 2026	INTS Intensity Therapeutics	-$0.8725	-$1.11	-$0.2375	-$1.11	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CALC CalciMedica	N/A	N/A	N/A	N/A	N/A
INTS Intensity Therapeutics	N/A	N/A	N/A	N/A	N/A
PSTV Plus Therapeutics	N/A	N/A	N/A	N/A	N/A
RDHL Redhill Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CALC CalciMedica	1.67	5.58	5.58
INTS Intensity Therapeutics	0.01	5.00	5.00
PSTV Plus Therapeutics	N/A	2.27	2.27
RDHL Redhill Biopharma	N/A	0.34	0.34

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CALC CalciMedica	N/A
INTS Intensity Therapeutics	3.74%
PSTV Plus Therapeutics	3.28%
RDHL Redhill Biopharma	7.20%

Insider Ownership

Company	Insider Ownership
CALC CalciMedica	28.25%
INTS Intensity Therapeutics	7.60%
PSTV Plus Therapeutics	2.50%
RDHL Redhill Biopharma	6.81%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CALC CalciMedica	15	6.83 million	4.90 million	No Data
INTS Intensity Therapeutics	2,021	3.26 million	3.02 million	Not Optionable
PSTV Plus Therapeutics	20	6.88 million	6.71 million	Not Optionable
RDHL Redhill Biopharma	210	6.08 million	5.67 million	No Data

RDHL, INTS, PSTV, and CALC Headlines

Recent News About These Companies

RedHill (RDHL) Acquires Rebyota and Clenpiq Commercialization Rights for $12M Upfront. Can Sales Outpace Royalties?

September 10, 2026 | finance.yahoo.com

RedHill acquires rights to Ferring’s Rebyota and Clenpiq

September 1, 2026 | thepharmaletter.comT

Redhill Biopharma stock doubles in one session — here's why

September 1, 2026 | msn.com

RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring’s Rebyota® and Clenpiq®

September 1, 2026 | markets.businessinsider.com

RedHill divests Talicia business to Apotex

September 1, 2026 | thepharmaletter.comT

RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring's Rebyota® and Clenpiq®

September 1, 2026 | prnewswire.com

RedHill Biopharma Stock Surges 64% Over Deal To Divest Talicia Business

August 31, 2026 | rttnews.com

RedHill Biopharma (NASDAQ: RDHL) Soars to $1.60 - Monetizes Talicia Stake in $18 Million Cash Deal With Apotex

August 31, 2026 | investorideas.comI

RedHill Divests Talicia® to Apotex for $18 Million Cash Upfront Plus Milestones to Fuel Strategic Growth Opportunities

August 31, 2026 | prnewswire.com

Redhill Biopharma Ltd (NASDAQ: RDHL) - Share Price and Research

August 8, 2026 | intelligentinvestor.com.auI

Ebola Cases and Deaths Rapidly Mount - RedHill Updates on Opaganib Emergency Outbreak Development

July 28, 2026 | prnewswire.com

RedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement

June 22, 2026 | prnewswire.com

RedHill Biopharma announces up to $19.4M private placement

June 18, 2026 | msn.com

RedHill Biopharma Announces Up To $19.4 Million Private Placement

June 18, 2026 | prnewswire.com

RedHill Biopharma Moves to Advance Opaganib as Oral Antiviral Option for Current Ebola Outbreak

June 13, 2026 | theglobeandmail.com

RedHill Biopharma Ltd.: RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation

June 9, 2026 | finanznachrichten.de

RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation

June 9, 2026 | prnewswire.com

RedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against Kukbo

June 8, 2026 | prnewswire.com

RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms

June 2, 2026 | prnewswire.com

Bessor Announces Entering Option for the Redhill Property

May 26, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

RDHL, INTS, PSTV, and CALC Company Descriptions

CalciMedica NASDAQ:CALC

$1.66 -0.02 (-1.19%)

As of 12:47 PM Eastern

CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.

Intensity Therapeutics NASDAQ:INTS

$3.54 -0.12 (-3.15%)

As of 12:52 PM Eastern

Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.

Plus Therapeutics NASDAQ:PSTV

$2.02 +0.03 (+1.51%)

As of 09/28/2026

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

Redhill Biopharma NASDAQ:RDHL

$0.49 -0.02 (-3.86%)

As of 12:51 PM Eastern

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RDHL, INTS, PSTV, and CALC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RDHL, INTS, PSTV, and CALC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RDHL, INTS, PSTV, and CALC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

RDHL, INTS, PSTV, and CALC Company Descriptions

CalciMedica NASDAQ:CALC

Intensity Therapeutics NASDAQ:INTS

Plus Therapeutics NASDAQ:PSTV

Redhill Biopharma NASDAQ:RDHL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RDHL, INTS, PSTV, and CALC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RDHL, INTS, PSTV, and CALC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RDHL, INTS, PSTV, and CALC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

RDHL, INTS, PSTV, and CALC Company Descriptions

CalciMedica NASDAQ:CALC

Intensity Therapeutics NASDAQ:INTS

Plus Therapeutics NASDAQ:PSTV

Redhill Biopharma NASDAQ:RDHL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools